In vitro evaluation of raft-forming and non-raft forming antacids marketed in India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250970Keywords:
Acid neutralization, Antacids, Digeraft Plus®, Gastroesophageal reflux disease, Rafts, Sodium alginateAbstract
Background: Raft properties of alginate‐antacids may vary based on their formulation. This study compared the physicochemical characteristics such as raft properties of Digeraft Plus® versus four other raft-forming (brands A to D) and acid neutralizing properties of raft-forming antacids versus two non-raft forming (brands E, F) antacids marketed in India.
Methods: The study assessed acid neutralizing capacity (ANC), and acid neutralizing potential (ANP) of the raft and non-raft forming antacids and the effect of raft structure on neutralization profile, raft strength, and raft resilience of the raft-forming antacids. Sodium alginate content of the raft-forming antacids was measured by a validated high-performance liquid chromatography (HPLC) assay.
Results: The raft-forming formulations were able to neutralize acid better than non-raft forming formulations. Total duration of acid neutralization of Digeraft Plus® was found to be 72±5.33 mins while for the other raft as well as non-raft forming antacid products, it was in the range of 40 to 60 mins. Additionally, it also had raft strength of around 20.5 gm which was significantly higher than other raft-forming brands (p<0.05) indicating enhanced raft integrity and retention. This performance correlates with its sodium alginate content, which was greater than 90%.
Conclusions: Results indicate that minor differences in formulation can affect the raft properties, and consequently, its in-vivo clinical efficacy. The strength and resilience of the rafts varied between the different alginate-based antacids available in the Indian market. Compared to other antacids, Digeraft Plus® had greater ANP, raft strength, and raft resilience.
Metrics
References
Vedavathi H, Tejasvi TS, Revankar SP. Evaluation of cost effectiveness and efficacy of commonly used different antacid gel preparations. Int J Basic Clin Pharmacol. 2013;2:788-91.
Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: a meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40:209-19.
Yousaf M, Nirwan JS, Smith AM, Timmins P, Conway BR, Ghori MU. Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): systematic review. J Appl Polymer Sci. 2019;136(40):48012.
Wang YK, Hsu WH, Wang SSW, Lu CY, Kuo FC, Su YC, et al. Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract. 2013;2013:1-12.
Goh K, Lee Y, Leelakusolvong S, Makmun D, Maneerattanaporn M, Quach DT, et al. Consensus statements and recommendations on the management of mild‐to‐moderate gastroesophageal reflux disease in the Southeast Asian region. JGH Open. 2021;5:855-63.
Moazen M, Shafaghi A, Ebrahimi-Najafabadi H, Ghasemi S, Ashoobi MT, Manoochehri S. Optimization of pH-sensitive ingredients and characterization of raft-forming alginate-based oral suspensions as reflux suppressant. J Drug Deliv Sci Technol. 2022;68:103124.
Johnson FA, Craig DQM, Mercer AD, Chauhan S. The effects of alginate molecular structure and formulation variables on the physical characteristics of alginate raft systems. Int J Pharm. 1997;159(1):35-42.
Hampson FC, Farndale A, Strugala V, Sykes J, Jolliffe IG, Dettmar PW. Alginate rafts and their characterisation. Int J Pharm. 2005;294:137-47.
Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: Alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Therap. 2000;14(6):669-90.
Savla HM, Naik IV, Gargote C, Shashidhar N, Nair S, Menon MD. Physicochemical properties of various alginate-based raft-forming antacid products: a comparative study. Int J Basic Clin Pharmacol. 2021;10:1330.
Dettmar PW, Gil-Gonzalez D, Fisher J, Flint L, Rainforth D, Moreno-Herrera A, et al. A comparative study on the raft chemical properties of various alginate antacid raft-forming products. Drug Dev Ind Pharm. 2018;44:30-9.
Yafout M, Elhorr H, El Otmani IS, Khayati Y. Evaluation of the acid-neutralizing capacity and other properties of antacids marketed in Morocco. Med Pharm Rep. 2022;95(1):80.
Ayensu I, Bekoe SO, Adu JK, Brobbey AA, Appiah E. Evaluation of acid neutralizing and buffering capacities of selected antacids in Ghana. Sci Afr. 2020;8:e00347.
Hampson FC, Jolliffe IG, Bakhtyari A, Taylor G, Sykes J, Johnstone LM, et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm. 2010;36:614-23.
Awad H, Aboul-Enein HY. A Validated HPLC Assay Method for the Determination of Sodium Alginate in Pharmaceutical Formulations. J Chromatogr Sci 2013;51:208-14.
British Pharmacopoeia Commission. British Pharmacopoeia. London: TSO; 2016.
Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34:59-66.
Tshiamala KKP, Oyeleke G, Nsokolo B, Aninagyei F, Sirwani R, Nair S. Comparative evaluation of Polygel Dual and commonly used alginate-antacid formulations (ACIDUAL Study). Trop J Pharm Res. 2023;21:2279-84.
Downloads
Published
How to Cite
Issue
Section
